OlalekanOlaniyiOluwoleMD

PubMed

• Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
  Markqayne D Ray, Eve H Limbrick-Oldfield, Sally W Wade, Steve Kanters, Anik R Patel, Olalekan O Oluwole, Sattva S Neelapu, Frederick L Locke> ;Expert Review of Anticancer Therapy. 2024 Apr 24
• Cost-effectiveness of axicabtagene ciloleucel for adult patients with relapsed or refractory follicular lymphoma in the United States.
  Markqayne D Ray, Katherine L Rosettie, Graeme Ball, Jorge Jacob, S Pinar Bilir, Anik R Patel, Olalekan O Oluwole, Caron A Jacobson> ;Value in Health. 2024 Apr 17
• Axicabtagene ciloleucel versus standard of care in second-line large B-cell lymphoma: outcomes by metabolic tumor volume.
  John Kuruvilla, Catherine Thieblemont, Franck Morschhauser, Steven P Rowe, Saran Vardhanabhuti, Joshua Winters, Simone Filosto, Christina To, Paul Cheng, Marco Schupp,...> ;Blood. 2024 Apr 1
• 3 citations
  Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium.
  Michael D Jain, Miriam T Jacobs, Feng Gao, Loretta J Nastoupil, Jay Y Spiegel, Yi Lin, Saurabh Dahiya, Matthew Lunning, Lazaros Lekakis, Patrick Reagan, Olalekan Oluwo...> ;Blood Advances. 2024 Feb 27
• 3 citations
  Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5).
  Epperla, N., Sattva S Neelapu, Julio C Chavez, Alison R Sehgal, Narendranath Epperla, Matthew Ulrickson, Emmanuel Bachy, Pashna N Munshi, Carla Casulo, David G Maloney...> ;Blood. 2024 Feb 8
• Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7.
  Ghobadi, A., Munoz, J., Westin, J., Locke, F., Miklos, D., Rapoport, A., Perales, M., Reagan, P., McGuirk, J., Jacobson, C., Kersten, M., Avivi, I., Peng, A., Schupp, ...> ;Blood Advances. 2024 Feb 5
• Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorpo...
  Ray, M., Davies, N., Bradford, R., Jones, C., Patel, A., Oluwole, O., Locke, F.> ;Journal of Medical Economics. 2024 Feb 13
• Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
  Olalekan O Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M Vose, Nancy L Bartlett, Yi Lin, Abhinav Deol, Peter McSweeney, Andre H Goy, Marie José Ke...> ;Bone Marrow Transplantation. 2024 Mar 1
• An updated cost-effectiveness analysis of axicabtagene ciloleucel in second-line large B-cell lymphoma patients in the United States.
  Patel, A., Vadgama, S., Smith, N., Blissett, R., Feng, C., Dickinson, M., Johnston, P., Oluwole, O., Perales, M.> ;Journal of Medical Economics. 2023 Dec 19
• Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
  Olalekan O Oluwole, Bhagirathbhai Dholaria, Tristan E Knight, Tania Jain, Frederick L Locke, Linda Ramsdell, Sarah Nikiforow, Hamza Hashmi, Kathy Mooney, Shakthi T Bha...> ;Transplantation and Cellular Therapy. 2024 Feb 1
• 3 citations
  Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy...
  Larry D Anderson Jr, Binod Dhakal, Tania Jain, Olalekan O Oluwole, Gunjan L Shah, Surbhi Sidana, Miguel-Angel Perales, Marcelo C Pasquini> ;Transplantation and Cellular Therapy. 2024 Jan 1
• 2 citations
  ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma.
  Zurko, J. C., Rezvani, A. R., Narendranath Epperla, Ambuj Kumar, Syed A Abutalib, Farrukh T Awan, Yi-Bin Chen, Ajay K Gopal, Jennifer Holter-Chakrabarty, Natasha Kekre...> ;Transplantation and Cellular Therapy. 2023 Sep 1
• 2 citations
  Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with bre...
  Bijal D Shah, Ryan D Cassaday, Jae H Park, Roch Houot, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzac...> ;Journal for Immunotherapy of Cancer. 2023 Aug 1
• 4 citations
  Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma.
  Michael Scordo, Jessica R Flynn, Mithat Gonen, Sean M Devlin, Allison Parascondola, Ana Alarcon Tomas, Roni Shouval, Jamie Brower, David L Porter, Stephen J Schuster, ...> ;Blood Advances. 2023 Sep 26
• 3 citations
  Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma.
  Mushtaq, M., Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, David L Porter, Sunita D Nasta, Jamie Brower, Veronika Bachanova, Marie Hu, Loretta J Nastoupil, O...> ;Transplantation and Cellular Therapy. 2023 Jul 1
• 8 citations
  Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma.
  Jason R Westin, Frederick L Locke, Michael Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David B Miklos, Matthew L Ulrickson, Miguel-Angel Perales, Umar F...> ;Clinical Cancer Research. 2023 May 15
• 7 citations
  Publisher Correction: Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
  Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, My...> ;Nature Medicine. 2023 Dec 1
• 50 citations
  Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma.
  Sattva S Neelapu, Caron A Jacobson, Armin Ghobadi, David B Miklos, Lazaros J Lekakis, Olalekan O Oluwole, Yi Lin, Ira Braunschweig, Brian T Hill, John M Timmerman, Abh...> ;Blood. 2023 May 11
• 36 citations
  Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium.
  Yucai Wang, Preetesh Jain, Frederick L Locke, Matthew J Maurer, Matthew J Frank, Javier L Munoz, Saurabh Dahiya, Amer M Beitinjaneh, Miriam T Jacobs, Joseph P Mcguirk,...> ;Journal of Clinical Oncology. 2023 May 10
• 59 citations
  Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.
  Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz, My...> ;Nature Medicine. 2023 Feb 1
• 3 citations
  Relapsed or refractory large B-cell lymphoma after chimeric antigen receptor T-cell therapy: Current challenges and therapeutic options.
  Raul Del Toro-Mijares, Olalekan Oluwole, Reena V Jayani, Adetola A Kassim, Bipin N Savani, Bhagirathbhai Dholaria> ;British Journal of Haematology. 2023 Apr 1
• 3 citations
  Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome.
  Shakthi T Bhaskar, David L Porter, Stephen J Schuster, Loretta J Nastoupil, Miguel-Angel Perales, Ana Alarcon Tomas, Michael R Bishop, Joseph P McGuirk, Richard T Mazi...> ;Blood Advances. 2023 Sep 12
• 18 citations
  Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an ...
  Bijal D Shah, Armin Ghobadi, Olalekan O Oluwole, Aaron C Logan, Nicolas Boissel, Ryan D Cassaday, Thibaut Leguay, Michael R Bishop, Max S Topp, Dimitrios Tzachanis, Kr...> ;Journal of Hematology & Oncology. 2022 Dec 10
• 9 citations
  Low toxicity and excellent outcomes in patients with DLBCL without residual lymphoma at the time of CD19 CAR T-cell therapy.
  Kitsada Wudhikarn, Ana Alarcon Tomas, Jessica R Flynn, Sean M Devlin, Jamie Brower, Veronika Bachanova, Loretta J Nastoupil, Joseph P McGuirk, Richard T Maziarz, Olale...> ;Blood Advances. 2023 Jul 11
• 32 citations
  Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Ce...
  Riedell, P., Hwang, W., Nastoupil, L., Pennisi, M., McGuirk, J., Maziarz, R., Bachanova, V., Oluwole, O., Brower, J., Flores, O., Ahmed, N., Schachter, L., Bharucha, K...> ;Transplantation and Cellular Therapy. 2022 Oct 1
• Join now to see all